

JAN. 7. 2005 8:46PM

GENAISSANCE PHARM.

NO. 132 P. 1



**GENAISSANCE
PHARMACEUTICALS**

**RECEIVED
CENTRAL FAX CENTER**

JAN 07 2005

**FIVE SCIENCE PARK
NEW HAVEN, CT 06511
TEL. 203.773.1450
FAX. 203.562.9377
WWW.GENAISSANCE.COM**

To: Mail Stop AF

Date: January 7, 2005

Company: Genaissance Pharmaceuticals, Inc

Pages: 9 (including cover sheet)

Fax Number: 703-872-9306

From: Melodie W. Henderson

Subject: Application No. 10/085,612

The document(s) accompanying this facsimile may contain information from Genaissance Pharmaceuticals that is confidential, proprietary, and/or legally privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or the taking of any action in reliance on the contents of this faxed information is strictly prohibited, and the document(s) should be returned to this company immediately. If you have received this fax in error, please notify us by telephone immediately, so that Genaissance may arrange for the return of the original document(s) at no cost to you.

JAN. 7. 2005 8:46PM

GENAISSANCE PHARM.


RECEIVED
CENTRAL FAX CENTER NO. 132 P. 2

JAN 07 2005

Appl. No. 10/085,612
Amendment dated January 7, 2005
Reply to Advisory Action mailed December 30, 2004

Application No. : 10/085,612 Confirmation No. 8119
Applicant : Marco Guida, et al.
Filed : February 26, 2002
Title : METHODS FOR EVALUATING THE ABILITY TO
METABOLIZE PHARMACEUTICALS AND COMPOSITIONS
THEREFOR
Art Unit : 1634
Examiner : Diana B. Johannsen
Attorney Docket No. : 4389-5-C1

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Facsimile Transmission
I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by
facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC
1600, at (703) 872-9306, on January 7, 2005.

Melodie W. Henderson

RESPONSE TO ADVISORY ACTION

This paper is submitted in response to the Final Rejection mailed November 12, 2004 and
the subsequent Advisory Action mailed December 30, 2004.

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this
paper.

Remarks begin on page 7 of this paper.